StockNews.com Begins Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

Equities researchers at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

NASDAQ:BLPH opened at $0.04 on Monday. Bellerophon Therapeutics has a one year low of $0.03 and a one year high of $0.10. The business’s 50-day simple moving average is $0.04 and its 200 day simple moving average is $0.04.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.